Insider · CIK 0001681955
Iain D. Dukes
Files at TRAW (Traws Pharma, Inc.), IOVA (IOVANCE BIOTHERAPEUTICS, INC.), Lomond Therapeutics Holdings, Inc.. First filing -, latest -.
Iain D. Dukes files SEC Form 4 as CEO, chair and director at TRAW (Traws Pharma, Inc.), and also at IOVA (IOVANCE BIOTHERAPEUTICS, INC.), Lomond Therapeutics Holdings, Inc.. No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Iain D. Dukes has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | AGrant or award Deferred Restricted Stock Unitderivative | +180,632 | $0.00 | $0 | 180,632 | Jun 18, 2026 |
| Mar 8, 2026 | TRAW Traws Pharma, Inc. | AGrant or award Stock Option (right to buy)derivative | +231,336 | $0.00 | $0 | 231,336 | Mar 10, 2026 |
| Dec 12, 2025 | TRAW Traws Pharma, Inc. | AGrant or award Common Stock | +36,943 | $0.00 | $0 | 171,130 | Dec 16, 2025 |
| Dec 12, 2025 | TRAW Traws Pharma, Inc. | AGrant or award Stock Option (right to purchase)derivative | +147,771 | $0.00 | $0 | 147,771 | Dec 16, 2025 |
| Oct 12, 2025 | TRAW Traws Pharma, Inc. | AGrant or award Stock Option (right to purchase)derivative | +64,839 | $0.00 | $0 | 64,839 | Oct 15, 2025 |
| Jun 13, 2025 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | AGrant or award Deferred Restricted Stock Unitderivative | +135,092 | $0.00 | $0 | 135,092 | Jun 17, 2025 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +2,096,667 | $0.00 | $0 | 2,096,667 | Nov 5, 2024 |
Questions about Iain D. Dukes
Answered from the filings on this page, as of the latest one.
Is Iain D. Dukes buying or selling?
Iain D. Dukes has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Iain D. Dukes's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Iain D. Dukes has 0.
Where does Iain D. Dukes file Form 4?
Iain D. Dukes has filed Form 4 at TRAW (Traws Pharma, Inc.) as Chief Executive Officer; IOVA (IOVANCE BIOTHERAPEUTICS, INC.); Lomond Therapeutics Holdings, Inc. as CEO and Chairman. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.